Li Chen1, Cai Cheng2, Bicui Chen1, Yue Zhao1, Jiming Zhang3, Bin Wang4. 1. Department of Pharmacy, HuaShan Hospital, Fudan University, No. 12 Middle Wu Lu Mu Qi Road, Shanghai, 200040, China. 2. College of Pharmacy, Fudan University, Shanghai, China. 3. Department of Infectious Diseases, HuaShan Hospital, Fudan University, No. 12 Middle Wu Lu Mu Qi Road, Shanghai, 200040, China. jmzhang@vip.126.com. 4. Department of Pharmacy, HuaShan Hospital, Fudan University, No. 12 Middle Wu Lu Mu Qi Road, Shanghai, 200040, China. wangbin@huashan.org.cn.
Abstract
PURPOSE: An increasing number of studies are reporting a high frequency of creatine kinase (CK) elevation during telbivudine therapy; however, few reports have focused on the cumulative incidence and risk factors of CK elevation. This study was performed to investigate the cumulative incidence and risk factors of CK elevation in Chinese patients treated with telbivudine. METHODS: In this observational study, patients with chronic hepatitis B receiving telbivudine therapy between July 2008 and December 2013 were enrolled. The cumulative incidence of CK elevation was analyzed using the Kaplan-Meier method combined with the log rank test. Risk factors were determined using Cox proportional hazards regression models. RESULTS: A total of 207 eligible patients were analyzed. The cumulative incidence of CK elevation at 12, 24, 36, 48, 60, and 72 months was 51.2 %, 68.9 %, 75.1 %, 78.1 %, 78.1 %, and 78.1 %, respectively. Multivariate analysis revealed that male and lower baseline estimated glomerular filtration rate (eGFR) were significant risk factors for CK elevation. CONCLUSIONS: The cumulative incidence of CK elevation after long-term telbivudine use is quite high, and gender and baseline eGFR may be useful predictors. However, when combined with regular monitoring of CK levels, especially for patients with lower eGFR, telbivudine is a relatively safe nucleoside analog treatment for chronic hepatitis B.
PURPOSE: An increasing number of studies are reporting a high frequency of creatine kinase (CK) elevation during telbivudine therapy; however, few reports have focused on the cumulative incidence and risk factors of CK elevation. This study was performed to investigate the cumulative incidence and risk factors of CK elevation in Chinese patients treated with telbivudine. METHODS: In this observational study, patients with chronic hepatitis B receiving telbivudine therapy between July 2008 and December 2013 were enrolled. The cumulative incidence of CK elevation was analyzed using the Kaplan-Meier method combined with the log rank test. Risk factors were determined using Cox proportional hazards regression models. RESULTS: A total of 207 eligible patients were analyzed. The cumulative incidence of CK elevation at 12, 24, 36, 48, 60, and 72 months was 51.2 %, 68.9 %, 75.1 %, 78.1 %, 78.1 %, and 78.1 %, respectively. Multivariate analysis revealed that male and lower baseline estimated glomerular filtration rate (eGFR) were significant risk factors for CK elevation. CONCLUSIONS: The cumulative incidence of CK elevation after long-term telbivudine use is quite high, and gender and baseline eGFR may be useful predictors. However, when combined with regular monitoring of CK levels, especially for patients with lower eGFR, telbivudine is a relatively safe nucleoside analog treatment for chronic hepatitis B.
Authors: Rao L Divi; Kathryn J Haverkos; Juliette A Humsi; Marie E Shockley; Chandrasekhar Thamire; Kunio Nagashima; Ofelia A Olivero; Miriam C Poirier Journal: Environ Mol Mutagen Date: 2007 Apr-May Impact factor: 3.216
Authors: Byung Kook Kim; Jeeyoung Oh; So Young Kwon; Won Hyeok Choe; Soon Young Ko; Kyoung Hoon Rhee; Tae Ho Seo; So Dug Lim; Chang Hong Lee Journal: J Hepatol Date: 2009-05-28 Impact factor: 25.083
Authors: Sònia López; Oscar Miró; Esteban Martínez; Enric Pedrol; Benjamín Rodríguez-Santiago; Ana Milinkovic; Anna Soler; Miguel A García-Viejo; Virginia Nunes; Jordi Casademont; Josep M Gatell; Francesc Cardellach Journal: Antivir Ther Date: 2004-02
Authors: Sangheun Lee; Jun Yong Park; Kijun Song; Do Young Kim; Beom Kyung Kim; Seung Up Kim; Hye Jin Ku; Kwang-Hyub Han; Sang Hoon Ahn Journal: Gut Liver Date: 2015-11-23 Impact factor: 4.519
Authors: Y Wang; S Thongsawat; E J Gane; Y-F Liaw; J Jia; J Hou; H L Y Chan; G Papatheodoridis; M Wan; J Niu; W Bao; A Trylesinski; N V Naoumov Journal: J Viral Hepat Date: 2012-12-27 Impact factor: 3.728